Cerity Partners
NVO

Cerity Partners’s Novo Nordisk NVO Stock Holding History

Cerity Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$676K Hold
18,400
– – ﹤0.01% 2100
2025
Q4 		$322K Buy
+18,400
New +$941K ﹤0.01% 2368

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Cerity Partners's NVO Position: Q1 2026 in Review

Cerity Partners reduced its Novo Nordisk (NVO) stake by 0.86% in Q1 2026, selling an estimated $195K and leaving 474,483 shares worth $17.4M. The position accounts for 0.02% of the portfolio, ranked #490.

Cerity Partners first reported a position in NVO in Q4 2017 and has held it in 21 quarters since. The position peaked at $94.1M in Q3 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Cerity Partners held 474,483 shares of Novo Nordisk worth $17.4M as of Q1 2026.
  • Cerity Partners sold 4,122 Novo Nordisk shares in Q1 2026, an estimated $195K.
  • Novo Nordisk made up 0.02% of Cerity Partners's portfolio in Q1 2026, its #490 holding.
  • Cerity Partners first reported a position in Novo Nordisk in Q4 2017 and has held it in 21 quarters since.
  • Cerity Partners's Novo Nordisk position peaked at $94.1M in Q3 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.